ITOS: the cashflow

MyFinsight

For the quarter ending 2025-06-30, ITOS had $65,709K increase in cash & cash equivalents over the period. -$76,594K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-06-30
Stock-based compensation	12,516
Net loss	-113,341
Prepaid expenses and other current assets	-833
Accrued personnel expenses	12,478
Deferred income	-125
Other accrued expenses	469
Accounts payable	-2,900
Unrealized foreign exchange loss	-415
Depreciation and amortization	664
Refundable income taxes	91
Net accretion of available-for-sale debt securities	-4,447
Unrecognized tax benefits	-2,070
Research and development tax credits receivable	493
Unbilled milestone receivable	0
Grants receivable	415
Accrued clinical trial costs	15,157
Change in operating lease right-of-use assets	-12
Net cash used in operating activities	-76,210
Proceeds from maturities of investments	225,047
Purchase of property and equipment	384
Purchase of other assets	26
Purchases of investments	89,991
Net cash provided by (used in) investing activities	134,646
Proceeds from issuance of common stock upon exercise of options and espp purchases	4,525
Net cash provided by financing activities	4,525
Effects of exchange rate changes on cash, cash equivalents and restricted cash	2,748
Net increase (decrease) in cash, cash equivalents and restricted cash	65,709

Unit: Thousand (K) dollars